The mutagenicity of the rodent carcinogen ethyl carbamate (EC, urethane) has been assessed using the lacZr transgenic mouse mutation assay (Muta™Mouse). In two separate experiments a single i.p. dose of 900 mg/kg urethane followed by a 14-16 day expression period yielded statistically significant (~2-fold) increases in mutation frequency (MF) in the lung and liver of the mice. In the second experiment MF hi the spleen and bone marrow was also assessed and statistically significant increases in MF were observed in each case. Concomitantly conducted bone marrow micronucleus assays gave 15.8-and 8-fold Increases respectively in the incidence of micronucleated polychromatic erythrocytes in the two studies.
Introduction
Ethyl carbamate (EC, urethane) is carcinogenic in mice, rats and hamsters following administration by the oral, inhalation, s.c. or i.p. routes. It produces lung tumours, hepatomas, lymphomas, melanomas and vascular tumours (IARC, 1974) . It is a potent clastogen when assessed using the mouse bone marrow micronucleus assay (Ashby et al, 1990; Holmstrom, 1990 ), but it is generally inactive in in vitro mutagenicity assays (reviewed in Sotomayor and Collins, 1990) . This inactivity in vitro has been associated with the absence of CYP2E1 from the S9 mix used in the in vitro assays, this isoenzyme being responsible for convertion of EC to DNAreactive species (Dahl et al, 1978; Ashby, 1991; Guengerich and Kim, 1991) .
EC-associated adducts are formed in the DNA of exposed rodents (Scherer etal., 1986; Fernando et al, 1996; Sotomayor and Washington, 1996) . In the mouse these adducts have been shown to be present in the lung and liver (Chavan and Bhide, 1972; Fernando et al, 1996) , the principal sites of EC-induced mouse carcinogenesis. In the present study the mutagenicity of EC to the lung, liver, spleen and bone marrow of lacZr transgenic mice (Muta™Mouse) was measured. In addition, bone marrow micronucleus assays were conducted using Muta™Mouse mice in order to determine the relative sensitivities of die micronucleus and the lacZr mutation assays.
Materials and methods

Chemicals and dose level selection
EC was obtained by further purification of material supplied by Aldrich (Gillingham, UK) as described previously (Ashby and Paton 1981) . The dose level of EC (900 mg/kg) was known to give a strong positive response in the mouse bone marrow micronucleus assay in the absence of acute toxicity (Ashby et al, 1990) .
Animals
Male Muta™Mouse mice were purchased from Hazelton USA, housed in a quarantine unit and maintained as described previously (Unwell et al, 1994a) . Animals aged between 14 and 16 weeks were used in the first study and between 34 and 36 weeks in the second study.
Micronucleus assays
These were conducted using male Muta™Mouse mice exactly as described earlier for non-transgenic mice (Tinwell and Ashby, 1989) . Animals were killed 24 h after dosing with an overdose of Fluothane, followed by cervical dislocation. Femurs were removed and bone marrow smears prepared and analysed as described previously (Tinwell and Ashby, 1989) . The incidence of micronucleated polychromatic erythrocytes (MPE) among 1000 polychromatic erythrocytes (PE) was determined by assessing 2000 PE/slide/animal. The ratio of PE to normochromatic erythrocytes (NE) was determined among 1000 erythrocytes from the same slides.
Mutation assays
Animals were killed 16 (experiment 1) or 14 days (experiment 2) after dosing. The lung, liver and bone marrow were taken and frozen at -80°C. In the second experiment the spleen was also taken. DNA was isolated from these tissues and processed for determination of mutation frequency using the galEp ositive selection protocol (Tinwell et al., 1994b ) with either Giga II or Giga III Pack Gold packaging systems (Stratagene). The mutation frequency (MF) was determined among a minimum of 200 000 plaque forming units (p.f.u.).
Study design
In the first study a group of 11 mice received a single i.p. dose of saline (10 ml/kg) and a further group of nine mice received EC (900 mg/kg) dissolved in saline. Six animals from each of the groups were used for the micronucleus assays and the remaining animals were used for the mutation analysis (five control and three test mice). In the second study groups of three (micronucleus assay) or seven (mutation assessment) mice were dosed with either saline or EC as described above.
Statistical analyses of data
Micronucleus data were assessed for statistical significance using a one-sided Student's /-test. Mutation assay data were analysed as proportions of mutants assessed using a generalized linear model with a binomial error and logit link function. Analyses were carried out separately for each organ and study using a model fitting group. Additionally, for the lung and liver only analyses were carried out with three terms: group to represent overall treatment effects, study to represent differences in overall levels across studies and a treatment X study interaction to represent differences in treatment effects between studies. Variances were inflated by the heterogeneity factor. The levels of statistical significance indicated are P < 0.05 and P < 0.01 (SAS Institute Inc., 1996) .
Results
Bone marrow micronucleus assays
The micronucleus assay data are shown in Table I . EC induced a 15.8-and an 8-fold increase respectively in the incidence of MPE in the two studies.
Mutation frequency analysis
At the time of tissue harvest it was noted that control animal number 13 had a grossly enlarged spleen. Elevated MFs were observed in some of the tissues examined from this animal and these data were excluded from the group means of all tissues. The MFs of the lung, liver and bone marrow of animals 18 and 19 (EC-treated) were less than those of the other ECtreated mice and probably indicated non-responsive animals. Lung. The MF values are shown in Table II . EC induced 2.2-'To whom correspondence should be addressed. Tel: +44 1625 512833; Fax: +44 1625 590249. and 2-fold increases respectively over the concurrent control MF in the two experiments (P < 0.05 and P < 0.01 respectively). Analyses of overall treatment study effects enhances the statistical significance to P < 0.01 for both studies. Liver. The MF values are shown in Table III . In the first study EC induced a 1.3-fold increase in MF in the liver when compared with the concurrent control data. This result was not statistically significant due to a clear outlier control animal with a MF of 130.6. Re-assessment of the data without this value gave a 1.6-fold increase in MF (P < 0.01). In the second study EC induced a 1.9-fold increase in MF (P < 0.01). Spleen. The MF values from the second experiment are shown in Table IV . A 1.6-fold increase in MF was observed (P < 0.01). Bone marrow. The MF values observed in the first experiment were highly variable for both the test and control animals (control MF range 32.2-351.1; test range 54.9-183.6; individual animal data not shown). These data were considered to be too variable to interpret and the experimental outcome was not formally assessed. The MF values from the second experiment are shown in Table V . EC induced a 1.7-fold increase in MF (P < 0.01).
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Discussion A summary of key published mutagenicity and carcinogenicity data for EC is given in Table VI . This chemical induces rapid onset of lung tumours and a high incidence of hepatomas in mice. However, it is generally found to be inactive in in vitro genotoxicity/mutagenicity assays. The positive bone marrow micronucleus assay responses observed for EC in the present study confirms the sensitivity of the Muta™Mouse strain of mice to the clastogenic activity of this chemical, as previously established in other strains of mice (Ashby et aL, 1990; Holmstrom, 1990; Ashby, 1991) . The clear nature of these bone marrow micronucleus assay data (Ashby et aL, 1990; Holmstrom, 1990; Ashby, 1991;  Table I ) further strengthens the general utility of this assay for definition of somatic cell rodent mutagens.
The gene mutagenic effects induced by EC in the lung and liver of the transgenic mice are consistent with the carcinogenic organotropism of this chemical (IARC, 1974; Bull et aL, 1984; Park et aL, 1993; Table VI) . Equally, the mutagenic effects seen in the spleen and bone marrow do not correlate with the carcinogenic organotropism of EC. It must be noted, however. Statistically significant compared with concurrent control (P < 0.01). that a full 2 year bioassay of EC in rats and mice has not yet been conducted and such a study might reveal additional sites of carcinogenic action. The bone marrow mutagenicity data for EC in the first transgenic mutation experiment were so variable that they could not be safely interpreted. Some of this variability may have been caused by the use of younger animals in that experiment. Similar variability in the MF of bone marrow DNA has been reported by another group of investigators (Hoorn et al., 1993) and it is interesting to note that relatively little bone marrow mutation data has so far been reported for transgenic mouse mutation assays.
In conclusion, the rodent carcinogen EC is mutagenic to several tissues of lacZ transgenic mice, including the lung and liver, the primary sites of its reported carcinogenicity in the mouse. The magnitude of these gene mutation inductions was weak, in contrast to the potent clastogenic effect observed in mouse bone marrow. The extent to which this divergence of effects may be related to the possible genetic specificity of mutagenic action of EC or to the fact that all of the gene mutations recorded were recorded in viable cells while some of the affected cells in the micronucleus assay may have died if left in the animal remains to be studied. Sirica et al. (1980) 
